Impact of organ-on-a-chip technology on pharmaceutical R&D costs

Nora Franzen, W. H. van Harten, Valesca P. Retèl, P. Loskill, J. van den Eijnden-van Raaij, Maarten IJzerman*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

4 Citations (Scopus)
20 Downloads (Pure)

Abstract

Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.

Original languageEnglish
Pages (from-to)1720-1724
Number of pages5
JournalDrug discovery today
Volume24
Issue number9
Early online date8 Jun 2019
DOIs
Publication statusPublished - 1 Sep 2019

Fingerprint

Pharmaceutical Technology
Costs and Cost Analysis
Technology
Drug Costs
Drug Discovery
Delivery of Health Care
Pharmaceutical Preparations

Cite this

@article{3ca7d6f87a284a0bbfba76b737d020f2,
title = "Impact of organ-on-a-chip technology on pharmaceutical R&D costs",
abstract = "Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.",
author = "Nora Franzen and {van Harten}, {W. H.} and Ret{\`e}l, {Valesca P.} and P. Loskill and {van den Eijnden-van Raaij}, J. and Maarten IJzerman",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.drudis.2019.06.003",
language = "English",
volume = "24",
pages = "1720--1724",
journal = "Drug discovery today",
issn = "1359-6446",
publisher = "Elsevier",
number = "9",

}

Impact of organ-on-a-chip technology on pharmaceutical R&D costs. / Franzen, Nora; van Harten, W. H.; Retèl, Valesca P.; Loskill, P.; van den Eijnden-van Raaij, J.; IJzerman, Maarten.

In: Drug discovery today, Vol. 24, No. 9, 01.09.2019, p. 1720-1724.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Impact of organ-on-a-chip technology on pharmaceutical R&D costs

AU - Franzen, Nora

AU - van Harten, W. H.

AU - Retèl, Valesca P.

AU - Loskill, P.

AU - van den Eijnden-van Raaij, J.

AU - IJzerman, Maarten

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.

AB - Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.

UR - http://www.scopus.com/inward/record.url?scp=85068251287&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2019.06.003

DO - 10.1016/j.drudis.2019.06.003

M3 - Review article

C2 - 31185290

AN - SCOPUS:85068251287

VL - 24

SP - 1720

EP - 1724

JO - Drug discovery today

JF - Drug discovery today

SN - 1359-6446

IS - 9

ER -